Comparison adjusted for multiplicity: [****] p<0.0001 for upadacitinib versus placebo.
PBO
UPA 15mg QD
0
10
20
30
50
[****]
40
60
% Responders
ASDAS-LDA
n=21 / N=209
n=93 / N=211
10
44
△
34.0%